Expression of cancer/testis antigens in salivary gland carcinomas with reference to <scp>MAGE</scp>‐A and <scp>NY</scp>‐<scp>ESO</scp>‐1 expression in adenoid cystic carcinoma

Beppu, Shintaro; Itô, Yôhei; Fujii, Kana; Saida, Kosuke; Takino, Hisashi; Awata, Masaki; Murase, Takayuki; Kusafuka, Kimihide; Iida, Yoshiyuki; Onitsuka, Tetsuro; Yatabe, Yasushi; Hanai, Nobuhiro; Hasegawa, Yasuhisa; Ijichi, Kei; Murakami, Shingo; Inagaki, Hiroshi

doi:10.1111/his.13226

Cited by 13 publications

(9 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The high rate of PRAME expression and its selective expression pattern, whereby it is expressed solely in TCs, make PRAME a possible diagnostic tool for detecting malignancy, and a promising target for cancer vaccination in SDC patients. Besides the current study, Harada et al . also studied the rates of expression of the CTAs MAGE‐A, NY‐ESO‐1, CT6 and GAGE7 in a cohort of 95 cases of salivary gland carcinoma, including 12 SDC patients.…”

Section: Discussionmentioning

confidence: 94%

“…CTAs are common tumour antigens that are specifically expressed in many solid cancer types, including HNSCC and salivary gland carcinoma. 23,[51][52][53][54][55][56] The expression of CTAs in adult human organs is limited to immune-privileged sites, e.g. the testis and, for some CTAs, occasionally the placenta and the brain.…”

Section: Discussionmentioning

confidence: 99%

“…Salivary duct carcinoma (SDC) is a high‐grade salivary gland malignancy that is resistant to chemotherapy and often follows an aggressive clinical course, with frequent local recurrence and metastasis . To date, little is known about the immune milieu, in particular PD‐1, PD‐L1, PRAME and MHC I expression in salivary gland malignancies in general and in SDC in particular . In order to address this need, we sought to assess PD‐1, PD‐L1, MHC I and PRAME immunoexpression in a retrospective cohort of 53 SDCs.…”

Section: Introductionmentioning

confidence: 99%

“…22 To date, little is known about the immune milieu, in particular PD-1, PD-L1, PRAME and MHC I expression in salivary gland malignancies in general and in SDC in particular. 4,[23][24][25] In order to address this need, we sought to assess PD-1, PD-L1, MHC I and PRAME immunoexpression in a retrospective cohort of 53 SDCs.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

The immune microenvironment and expression of PD‐L1, PD‐1, PRAME and MHC I in salivary duct carcinoma

Jungbluth

Frosina

et al. 2019

Histopathology

View full text Add to dashboard Cite

Aims Salivary duct carcinoma (SDC) is an aggressive salivary malignancy that results in high mortality rates and is often resistant to chemotherapy. Anti‐programmed death‐1 (PD‐1)/programmed death ligand‐1 (PD‐L1) checkpoint inhibitors have led to dramatic improvements in patients with various cancers. Other immunotherapeutic approaches, e.g. cancer vaccines, have shown promising results. Cancer testis antigens, e.g. preferentially expressed antigen in melanoma (PRAME), are regarded as promising vaccine targets because of their tumour‐specific expression pattern. Methods and results We analysed the immunoexpression of PD‐L1, PD‐1, major histocompatibility complex class I (MHC I) and PRAME in 53 SDCs. The immunoexpression levels of PD‐L1 in tumour cells (TCs) and immune cells (ICs), PD‐1 in ICs, PRAME in TCs and MHC I in TCs were analysed, and were correlated with outcome. PRAME expression was seen in 83% of SDCs. No PRAME staining was present in normal salivary gland tissue. With the three established diagnostic algorithms proposed for head and neck squamous cell carcinoma, the criteria being a combined positive score of ≥1, TC% ≥1%, and TC% ≥25%, 35 (66%), 17 (32%) and three cases (6%), respectively, were deemed to be positive for PD‐L1. PD‐1‐positive ICs were seen in 35 (66%) cases. MHC I down‐regulation was seen in 82% of SDCs. There was a significant correlation among PD‐L1 expression in ICs, PD‐1 expression in ICs, and PRAME expression in TCs. PD‐L1 expression in TCs and lack of PD‐1 expression in ICs were associated with decreased disease‐specific survival in SDC patients. Conclusions Alterations of the tumour immune microenvironment are common in SDCs, including expression of PD‐1/PD‐L1 and PRAME, which opens the way to potential novel immune therapies, such as cancer vaccination and PD‐1/PD‐L1 blockade, in these tumours.

show abstract

Section: Discussionmentioning

confidence: 94%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The immune microenvironment and expression of PD‐L1, PD‐1, PRAME and MHC I in salivary duct carcinoma

Jungbluth

Frosina

et al. 2019

Histopathology

View full text Add to dashboard Cite

show abstract

“…In addition, AKAP4, a scaffolding protein that regulates intracellular signaling, is aberrantly expressed in PCa and a potential target for PCa anti‐tumor vaccination or adoptive immunotherapy . The highly immunogenic and well‐characterized CTA, NY‐ESO‐1 , is also expressed in a proportion of localized PCa and hormone refractory PCa cases .…”

mentioning

confidence: 99%

Cancer/testis antigen SPATA19 is frequently expressed in benign prostatic hyperplasia and prostate cancer

Wong

Hussain

Loo

et al. 2017

APMIS

View full text Add to dashboard Cite

Spermatogenesis-associated 19 (SPATA19) is a cancer/testis antigen overexpressed in various cancers. However, its protein expression profile in malignant or non-malignant tissues remains unknown. Thus, in this study, we investigated SPATA19 protein expression patterns in a panel of non-malignant human samples and primary prostate cancer (PCa) with or without benign prostatic hyperplasia (BPH) tissues. SPATA19 was absent in all non-malignant tissues investigated (n=14) except testis and prostate tissues. In terms of malignancies, all PCa cases were positive for SPATA19 exhibiting frequency between 20 and 100% (median 85%) with 63 (52.5%) and 57 (47.5%) cases demonstrating weak/moderate and strong intensities, respectively. Thirty-nine PCa cases (32.5%) contained BPH, and all BPH glands were SPATA19 positive (frequency between 20 and 100%; median 90%) with 13 (33.3%) demonstrating strong SPATA19 expression. Higher SPATA19 expression (higher frequency, intensity, or H-score) was not associated with overall survival or disease-specific survival (DFS) in all PCa cases. However, biochemical recurrence (BR) was associated with worse DFS (p = 0.005) in this cohort of 120 patients, and cases with strong SPATA19 intensity were associated with BR (p = 0.020). In conclusion, we showed that SPATA19 protein was frequently expressed in both BPH and PCa glands, and this warrants future investigations on its pathogenic roles in the disease.

show abstract

Prostate cancer health disparities: An immuno-biological perspective

et al. 2018

View full text Add to dashboard Cite

Prostate cancer (PCa) is the most commonly diagnosed malignancy in males, and, in the United States, is the second leading cause of cancer-related death for men older than 40 years. There is a higher incidence of PCa for African Americans (AAs) than for European-Americans (EAs). Investigations related to the incidence of PCa-related health disparities for AAs suggest that there are differences in the genetic makeup of these populations. Other differences are environmentally induced (e.g., diet and lifestyle), and the exposures are different. Men who immigrate from Eastern to Western countries have a higher risk of PCa than men in their native countries. However, the number of immigrants developing PCa is still lower than that of men in Western countries, suggesting that genetic factors are involved in the development of PCa. Altered genetic polymorphisms are associated with PCa progression. Androgens and the androgen receptor (AR) are involved in the development and progression of PCa. For populations with diverse racial/ethnic backgrounds, differences in lifestyle, diet, and biology, including genetic mutations/polymorphisms and levels of androgens and AR, are risk factors for PCa. Here, we provide an immuno-biological perspective on PCa in relation to racial/ethnic disparities and identify factors associated with the disproportionate incidence of PCa and its clinical outcomes.

show abstract

Expression of cancer/testis antigens in salivary gland carcinomas with reference to MAGE‐A and NY‐ESO‐1 expression in adenoid cystic carcinoma

Cited by 13 publications

References 34 publications

The immune microenvironment and expression of PD‐L1, PD‐1, PRAME and MHC I in salivary duct carcinoma

The immune microenvironment and expression of PD‐L1, PD‐1, PRAME and MHC I in salivary duct carcinoma

Cancer/testis antigen SPATA19 is frequently expressed in benign prostatic hyperplasia and prostate cancer

Prostate cancer health disparities: An immuno-biological perspective

Contact Info

Product

Resources

About